Publication Name	World Journal of Transplantation
Manuscript ID	100041
Country	United States

Category	Transplantation
Manuscript Type	Retrospective Cohort Study
Article Title	Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature
Manuscript Source	Invited Manuscript
All Author List	Alissar El Chediak, Dhruv Ahuja, Cassandra Bruns, Rachael Simard, Kellie Spence, Amna Gul, Rachel C Forbes and Beatrice P Concepcion
Funding Agency and Grant Number
Corresponding Author	Beatrice P Concepcion, Associate Professor, MD, Department of Medicine, Section of Nephrology, University of Chicago, 5841 S. Maryland Ave MC 5100, Chicago, IL 60637, United States. beatrice.concepcion@bsd.uchicago.edu
Key Words	Pre-exposure prophylaxis; kidney transplant; COVID-19; SARS-CoV-2; tixagevimab/cilgavimab; Early posttransplant period
Core Tip	This study reports on the use of tixagevimab/cilgavimab in newly transplanted kidney recipients. There were no adverse events related to the drug, and a 12.5% breakthrough infection rate, 4.5% hospitalization rate, and no deaths. The results suggest reassuring outcomes in newly transplanted kidney recipients who received tixagevimab/cilgavimab 300 mg/300 mg as prevention for coronavirus disease 2019 during the omicron wave. A systematic literature review of studies reporting outcomes of solid organ transplant recipients who received tixagevimab/cilgavimab found that the drug was well tolerated and a higher dose (300 mg/300 mg) was more protective against breakthrough infections and hospitalization than the lower dose (150 mg/150 mg).
Citation	El Chediak A, Ahuja D, Bruns C, Simard R, Spence K, Gul A, Forbes RC, Concepcion BP. Prophylactic role of Tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature. World J Transplant 2025; In press

Received	2024-08-14 02:12
Peer-Review Started	2024-08-05 18:15
To Make the First Decision
Return for Revision	2024-12-11 06:48
Revised	2025-02-23 23:23
Second Decision	2025-04-16 02:49
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-04-16 07:32
Articles in Press	2025-04-16 07:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-05-30 12:57

ISSN	2220-3230 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com